{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:17:55Z","timestamp":1783905475032,"version":"3.55.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000155","name":"Social Sciences and Humanities Research Council of Canada","doi-asserted-by":"publisher","award":["430-2021-00340"],"award-info":[{"award-number":["430-2021-00340"]}],"id":[{"id":"10.13039\/501100000155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Global Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>During the COVID-19 pandemic corruption risks were amplified in health systems globally, increasing health inequities within and between countries. During the pandemic, the deployment of COVID-19 vaccines, particularly concerning their procurement and distribution, had corruption risks given the large amounts of public and private funding allocated to them, the need for speed, the involvement of a high number of stakeholders, and often insufficient oversight. To explore this issue further, we conducted a descriptive, qualitative study of corruption risks in the COVID-19 vaccine deployment process.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a descriptive, qualitative study triangulating two data sources between May and August 2022: (1) published academic and grey literature and (2) key informant interviews with representatives from organizations involved with the COVAX Facility, representatives from COVAX donor and recipient countries, and individuals with expert knowledge of the COVID-19 vaccine deployment process (e.g., consultants for international organizations involved in COVID-19 vaccine deployment, members of non-governmental organizations, etc.).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified 44 academic articles and policy documents and triangulated. Documentary data with 16 key informant interviews. A review of the literature identified several corruption risks in the international COVID-19 vaccine procurement and distribution process such as a lack of transparency in the vaccine procurement process; a lack of transparency in the operation of the COVAX Facility; a risk of bribery; and a risk of vaccine theft or the introduction of substandard and falsified vaccines at the point of distribution. Key informants further articulated concerns about a lack of transparency in vaccine pricing and contracts and the exclusion of civil society organizations from the vaccine deployment process. Reported anti-corruption, transparency, and accountability (ACTA) mechanisms implemented across the many levels of the vaccine procurement and distribution deployment included institutional oversight processes, blockchain-based supply-chain solutions, and civil society engagements.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Public health emergencies require nimble and quick actions on the part of governments, international organizations and other actors Our study on the COVID-19 vaccine deployment process highlights the pressing need for more robust ACTA mechanisms to reduce corruption risks and ensure fair and equitable access to lifesaving vaccines for populations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12992-025-01096-6","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:32:21Z","timestamp":1741347141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Corruption risks in COVID-19 vaccine deployment: lessons learned for future pandemic preparedness"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6222-3275","authenticated-orcid":false,"given":"Gul","family":"Saeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian Clare","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"1096_CR1","unstructured":"Transparency International. What is Corruption? [Internet]. n.d. a [cited 2021 Sep 26]. Available from: https:\/\/www.transparency.org\/en\/what-is-corruption"},{"key":"1096_CR2","doi-asserted-by":"publisher","unstructured":"Mackey TK, Kohler J, Lewis M, Vian T. Combating corruption in global health. Sci Transl Med [Internet]. 2017;(402):eaaf9547. Available from: https:\/\/www.science.org\/doi\/https:\/\/doi.org\/10.1126\/scitranslmed.aaf9547","DOI":"10.1126\/scitranslmed.aaf9547"},{"key":"1096_CR3","doi-asserted-by":"publisher","unstructured":"Kohler JC, Chang Pico T, Vian T, Mackey TK. The Global Wicked Problem of Corruption and Its Risks for Access to HIV\/AIDS Medicines. Clinical Pharmacology & Therapeutics [Internet]. 2018;104(6):1054\u20136. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/cpt.1172","DOI":"10.1002\/cpt.1172"},{"issue":"sup1","key":"1096_CR4","doi-asserted-by":"publisher","first-page":"1694745","DOI":"10.1080\/16549716.2019.1694745","volume":"13","author":"JC Kohler","year":"2020","unstructured":"Kohler JC, Dimancesco D. The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk. Glob Health Action. 2020;13(sup1):1694745.","journal-title":"Glob Health Action"},{"key":"1096_CR5","unstructured":"Kohler J, Martinez G. Mapping corruption risks in the pharmaceuticals and Healthcare sectors. Transparency International; 2015."},{"key":"1096_CR6","unstructured":"Bruckner T. The Ignored Pandemic - Transparency International Global Health [Internet]. 2019 [cited 2021 Sep 26]. Available from: https:\/\/ti-health.org\/content\/the-ignored-pandemic\/"},{"key":"1096_CR7","unstructured":"United Nations. Health [Internet]. United Nations Sustainable Development. n.d. a [cited 2021 Sep 26]. Available from: https:\/\/www.un.org\/sustainabledevelopment\/health\/"},{"key":"1096_CR8","unstructured":"United Nations. SDG #16 [Internet]. United Nations Sustainable Development Goals. n.d. b [cited 2021 Sep 26]. Available from: https:\/\/sdgs.un.org\/goals\/goal16"},{"key":"1096_CR9","unstructured":"UN Secretary-General. Corruption is the ultimate betrayal of public trust [Internet]. United Nations. United Nations. 2020 [cited 2021 Sep 26]. Available from: https:\/\/www.un.org\/en\/coronavirus\/statement-corruption-context-covid-19"},{"key":"1096_CR10","unstructured":"United Nations. The Sustainable Development Goals Report 2022 [Internet]. United Nations. 2022 [cited 2021 Sep 26). Available from: https:\/\/unstats.un.org\/sdgs\/report\/2022\/The-Sustainable-Development-Goals-Report-2022.pdf"},{"key":"1096_CR11","doi-asserted-by":"publisher","unstructured":"Saeed G, Kohler JC, Cuomo RE, Mackey TK. A systematic review of digital technology and innovation and its potential to address anti-corruption, transparency, and accountability in the pharmaceutical supply chain. Expert Opinion on Drug Safety [Internet]. 2022 Aug 3 [cited 2023 Feb 8];21(8):1061\u201388. Available from: https:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/14740338.2022.2091543","DOI":"10.1080\/14740338.2022.2091543"},{"key":"1096_CR12","unstructured":"United Nations Office on Drugs and Crime (UNODC). COVID-19 Vaccines and Corruption Risks: Preventing Corruption in the Manufacture, Allocation and Distribution of Vaccines [Internet]. UNODC. 2020 [cited 2021 Sep 26]. Available from: https:\/\/www.unodc.org\/documents\/corruption\/COVID-19\/Policy_paper_on_COVID-19_vaccines_and_corruption_risks.pdf"},{"key":"1096_CR13","doi-asserted-by":"publisher","unstructured":"Rose -AckermanS. Corruption and Covid-19. Eunom\u00eda. Revista en Cultura de la Legalidad. 2021 [cited 2024 Apr 9];20:16\u201336. Available from: https:\/\/doi.org\/10.20318\/eunomia.2021.6061","DOI":"10.20318\/eunomia.2021.6061"},{"key":"1096_CR14","doi-asserted-by":"publisher","unstructured":"Kohler JC, Wright T. The Urgent Need for Transparent and Accountable Procurement of Medicine and Medical Supplies in Times of COVID-19 Pandemic. J of Pharm Policy and Pract [Internet]. 2020;13(1):58. Available from: https:\/\/joppp.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40545-020-00256-w","DOI":"10.1186\/s40545-020-00256-w"},{"key":"1096_CR15","unstructured":"Transparency International. Transparency in Health Sector Procurement (G20 Position Paper) [Internet]. Transparency International UK. 2016 [cited 2021 Sep 26]. Available from: https:\/\/www.transparency.org\/files\/content\/pages\/TI_G20_position_paper_-_health_sector_procurement_transparency.pdf"},{"key":"1096_CR16","unstructured":"Rhodes N, Wright T, Rusu V, Bakhtari H, Cushing J, Kohler J. For Whose Benefit? Transparency in the development and procurement of COVID-19 vaccines [Internet]. Transparency International. 2021 [cited 2021 Sep 26]. Available from: https:\/\/ti-health.org\/wp-content\/uploads\/2021\/05\/For-Whose-Benefit-Transparency-International.pdf"},{"key":"1096_CR17","doi-asserted-by":"publisher","unstructured":"Vian T, Kohler JC, Forte G, Dimancesco D. Promoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency alliance. J of Pharm Policy and Pract [Internet]. 2017;10(1):18. Available from: http:\/\/joppp.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40545-017-0106-x","DOI":"10.1186\/s40545-017-0106-x"},{"key":"1096_CR18","unstructured":"OECD. Preventing Corruption in Public Procurement [Internet]. 2016 [cited Sept 26]. Available from: https:\/\/www.oecd.org\/gov\/ethics\/Corruption-Public-Procurement-Brochure.pdf"},{"key":"1096_CR19","unstructured":"WHO. 172 countries and multiple candidate vaccines engaged in COVID-19 vaccine Global Access Facility [Internet]. 2020 [cited 2021 Sep 27]. Available from: https:\/\/www.who.int\/news\/item\/24-08-2020-172-countries-and-multiple-candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility"},{"key":"1096_CR20","unstructured":"Gavi, the Vaccine Alliance. COVAX explained [Internet]. 2020a [cited 2021 Sep 27]. Available from: https:\/\/www.gavi.org\/vaccineswork\/covax-explained"},{"key":"1096_CR21","doi-asserted-by":"crossref","unstructured":"de Bengy Puyvall\u00e9e A, Storeng KT. COVAX, vaccine donations and the politics of global vaccine inequity. Globalization and health. 2022 [cited 2024 Apr 9];18(1):26\u201326.","DOI":"10.1186\/s12992-022-00801-z"},{"key":"1096_CR22","unstructured":"WHO. COVAX Working for global equitable access to COVID-19 vaccines [Internet]. n.d. [cited 2024 Apr 9]. Available from: https:\/\/www.who.int\/initiatives\/act-accelerator\/covax"},{"key":"1096_CR23","unstructured":"GAVI. COVAX Facility governance explained [Internet]. 2020 [cited 2024 Apr 9]. Available from: https:\/\/www.gavi.org\/vaccineswork\/covax-facility-governance-explained"},{"key":"1096_CR24","unstructured":"Ducharme J. COVAX Was a Great Idea, But Is Now 500 Million Doses Short of Its Vaccine Distribution Goals. What Exactly Went Wrong? [Internet] TIME. 2021, Sept 9 [cited 2024 Apr 4]. Available from: https:\/\/time.com\/6096172\/covax-vaccines-what-went-wrong\/"},{"issue":"1","key":"1096_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12992-023-00994-x","volume":"19","author":"KA Griffore","year":"2023","unstructured":"Griffore KA, Bowra A, Guilcher SJT, Kohler J. Corruption risks in health procurement during the COVID-19 pandemic and anti-corruption, transparency and accountability (ACTA) mechanisms to reduce these risks: a rapid review. Globalization Health. 2023;19(1):91. https:\/\/doi.org\/10.1186\/s12992-023-00994-x.","journal-title":"Globalization Health"},{"key":"1096_CR26","unstructured":"Wolters Kluwer Health, Inc. Expert Searches [Internet]. OVID. n.d. a [cited 2021 Oct 24]. Available from: from https:\/\/tools.ovid.com\/ovidtools\/expertsearches.html"},{"key":"1096_CR27","unstructured":"Barnes J. Book Review by John Barnes: Qualitative Research Practice: A Guide for Social Science Students and Researchers, 2e, 2014. Jane Ritchie, Jane Lewis, Carol McNaughton Nicholls and Rachel Ormston, editors. AU-GSB E-Journal. Bangkok: Assumption University Press; 2018;11(1):58&#8211."},{"key":"1096_CR28","doi-asserted-by":"crossref","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating Rigor Using Thematic Analysis: A Hybrid Approach of Inductive and Deductive Coding and Theme Development. International journal of qualitative methods. 2006;5(1):80\u201392. Available from: https:\/\/journals.sagepub.com\/doi\/10.1177\/160940690600500107","DOI":"10.1177\/160940690600500107"},{"key":"1096_CR29","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative research in psychology. 2006;3(2):77\u2013101. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1191\/1478088706qp063oa","DOI":"10.1191\/1478088706qp063oa"},{"key":"1096_CR30","unstructured":"Apuzzo M, Gebrekidan S. Governments Sign Secret Vaccine Deals. Here\u2019s What They Hide [Internet]. The New York Times. 2021 Feb 24 [cited 2021 Oct 5]. Available from: https:\/\/www.nytimes.com\/2021\/01\/28\/world\/europe\/vaccine-secret-contracts-prices.html"},{"issue":"20","key":"1096_CR31","doi-asserted-by":"publisher","first-page":"30297","DOI":"10.1007\/s11356-022-18536-0","volume":"29","author":"M Usman","year":"2022","unstructured":"Usman M, Husnain M, Akhtar MW, Ali Y, Riaz A, Riaz A. From the COVID-19 pandemic to corrupt practices: a tale of two evils. Environ Sci Pollut Res Int. 2022;29(20):30297\u2013310.","journal-title":"Environ Sci Pollut Res Int"},{"issue":"10","key":"1096_CR32","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/vaccines9101183","volume":"9","author":"M Sung","year":"2021","unstructured":"Sung M, Huang Y, Duan Y, Liu F, Jin Y, Zheng Z. Pharmaceutical Industry\u2019s Engagement in the global Equitable distribution of COVID-19 vaccines: corporate social responsibility of EUL Vaccine Developers. Vaccines (Basel). 2021;9(10):1183.","journal-title":"Vaccines (Basel)"},{"key":"1096_CR33","unstructured":"Hussman K. Global access to Covid-19 vaccines: Lifting the veil of opacity [Internet]. U4 Anti-Corruption Resource Centre, Chr. Michelsen Institute. 2021 [cited 2021 Oct 24]. Available from: https:\/\/www.u4.no\/publications\/lifting-the-veil-of-opacity-in-covid-19-vaccines-to-combat-the-pandemic"},{"key":"1096_CR34","unstructured":"Gavi, the Vaccine Alliance. Risk & Assurance Report 2021 [Internet]. GAVI. 2021 [cited 2021 Oct 24]. Available from: https:\/\/www.gavi.org\/sites\/default\/files\/document\/strategy\/Risk-and-Assurance-Report-2021.pdf"},{"key":"1096_CR35","unstructured":"Gavi, the Vaccine Alliance. Risk & Assurance Report 2020 [Internet]. GAVI. 2020b [cited 2021 Oct 24]. Available from: https:\/\/www.gavi.org\/sites\/default\/files\/document\/strategy\/Risk-and-Assurance-Report-2020.pdf"},{"issue":"1","key":"1096_CR36","doi-asserted-by":"publisher","first-page":"23423","DOI":"10.1038\/s41598-021-02802-1","volume":"11","author":"MR Farzanegan","year":"2021","unstructured":"Farzanegan MR, Hofmann HP. Effect of public corruption on the COVID-19 immunization progress. Sci Rep. 2021;11(1):23423\u201323423. Available from:.","journal-title":"Sci Rep"},{"key":"1096_CR37","doi-asserted-by":"publisher","unstructured":"Goel RK, Nelson MA, Goel VY. COVID-19 vaccine rollout-scale and speed carry different implications for corruption. Journal of policy modeling. 2021[cited 2024 Apr 8];43(3):503\u2013520. Available from: https:\/\/doi.org\/10.1016\/j.jpolmod.2021.04.003","DOI":"10.1016\/j.jpolmod.2021.04.003"},{"key":"1096_CR38","unstructured":"Transparency International. Transparency and corruption in COVID-19 vaccine deployment: Evidence from Bangladesh, Uganda, and Zambia [Internet]. 2022 [cited 2021 Oct 27]. Available from: https:\/\/ti-health.org\/wp-content\/uploads\/2022\/05\/TRANSPARENCY-AND-CORRUPTION-IN-COVID-19-VACCINE-DEPLOYMENT.pdf"},{"key":"1096_CR39","unstructured":"Hauck G. Cutting, bribing, stealing: Some people get COVID-19 vaccines before it\u2019s their turn [Internet]. USA TODAY. 2021 February 3 [cited 2021 Oct 27]. Available from: https:\/\/www.usatoday.com\/story\/news\/health\/2021\/02\/03\/covid-vaccine-some-people-cutting-bribing-before-their-turn\/4308915001\/"},{"key":"1096_CR40","unstructured":"Rahman K. Mitigating corruption risks in Covid-19 vaccine rollout: What can donors do? [Internet]. U4 Anti-Corruption Resource Centre, Chr. Michelsen Institute. 2021 [cited 2021 Oct 27]. Available from: https:\/\/www.u4.no\/publications\/mitigating-corruption-risks-in-covid-19-vaccine-rollout"},{"key":"1096_CR41","unstructured":"UNICEF. COVID-19 Vaccine Market Dashboard [Internet]. n.d. [cited 2023 Feb 8]. Available from: https:\/\/www.unicef.org\/supply\/covid-19-vaccine-market-dashboard"},{"issue":"1","key":"1096_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12992-022-00801-z","volume":"18","author":"A de Bengy Puyvall\u00e9e","year":"2022","unstructured":"de Bengy Puyvall\u00e9e A, Storeng KT. COVAX, vaccine donations and the politics of global vaccine inequity. Globalization Health. 2022;18(1):26\u201326.","journal-title":"Globalization Health"},{"key":"1096_CR43","doi-asserted-by":"publisher","first-page":"04165","DOI":"10.7189\/jogh.13.04165","volume":"13","author":"A Gorodensky","year":"2023","unstructured":"Gorodensky A, Grundy Q, Persaud N, Kohler JC. Shared health governance, mutual collective accountability, and transparency in COVAX: a qualitative study triangulating data from document sampling and key informant interviews. J Global Health. 2023;13:04165. https:\/\/doi.org\/10.7189\/jogh.13.04165.","journal-title":"J Global Health"},{"key":"1096_CR44","doi-asserted-by":"publisher","unstructured":"Taylor L. Covid-19: Vaccine corruption allegations spark protests across Brazil. BMJ. 2021 Jul 6 [cited 2024 Apr 9];374:n1724. Available from: https:\/\/doi.org\/10.1136\/bmj.n1724","DOI":"10.1136\/bmj.n1724"},{"key":"1096_CR45","unstructured":"Uzomah HO, UNDERSTANDING THE EXISTENTIAL CHALLENGES, OF COVID 19 VACCINE DEVELOPMENT AND PROCUREMENT IN AFRICA: EMPHASIS ON SOUTH AFRICA, Gender, Behaviour. Suppl.Special Edition. 2021 [cited 2024 Apr 9];19(1):17536\u201317548. Available from: https:\/\/www.proquest.com\/scholarly-journals\/understanding-existential-challenges-covid-19\/docview\/2649773112\/se-2"},{"issue":"5","key":"1096_CR46","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.4269\/ajtmh.21-0448","volume":"105","author":"MF Wardak","year":"2021","unstructured":"Wardak MF, Rahimi A, Ahmadi A, Madadi S, Arif S, Nikbin AM, et al. COVID-19 vaccination efforts: is Afghanistan prepared? Am J Trop Med Hyg. 2021;105(5):1137\u201340.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"1096_CR47","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12992-022-00802-y","volume":"18","author":"SJ Peacock","year":"2022","unstructured":"Peacock SJ. Vaccine nationalism will persist: global public goods need effective engagement of global citizens. Globalization Health. 2022;18(1):14\u201314.","journal-title":"Globalization Health"},{"key":"1096_CR48","unstructured":"UNDP. Global Dashboard for Vaccine Equity - UNDP Data Futures Platform [Internet]. n.d. [cited 2022 July 27]. Available from: https:\/\/data.undp.org\/vaccine-equity\/"},{"key":"1096_CR49","doi-asserted-by":"crossref","unstructured":"Spreco A, Sch\u00f6n T, Timpka T. Corruption should be taken into account when considering COVID-19 vaccine allocation. Proceedings of the National Academy of Sciences - PNAS. 2022;119(19):e2122664119\u2013e2122664119.","DOI":"10.1073\/pnas.2122664119"},{"key":"1096_CR50","doi-asserted-by":"crossref","unstructured":"Bollyky TJ, Hulland EN, Barber RM, Collins JK, Kiernan S, Moses M et al. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021. Lancet (London, England). 2022;399(10334):1489\u2013512.","DOI":"10.1016\/S0140-6736(22)00172-6"},{"issue":"1","key":"1096_CR51","doi-asserted-by":"publisher","first-page":"22440","DOI":"10.1038\/s41598-021-01831-0","volume":"11","author":"M Tatar","year":"2021","unstructured":"Tatar M, Faraji MR, Montazeri Shoorekchali J, Pag\u00e1n JA, Wilson FA. The role of good governance in the race for global vaccination during the COVID-19 pandemic. Sci Rep. 2021;11(1):22440\u201322440.","journal-title":"Sci Rep"},{"issue":"2","key":"1096_CR52","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1093\/pubmed\/fdab092","volume":"43","author":"MDM Dela Cruz","year":"2021","unstructured":"Dela Cruz MDM, Mendoza AJM, Gueco GEA, Maghinang CJMP, Gopez JMW. Transparency of the national government as key in promoting the rollout of COVID-19 vaccines. J Public Health (Oxf). 2021;43(2):e381\u20132.","journal-title":"J Public Health (Oxf)"},{"issue":"4","key":"1096_CR53","doi-asserted-by":"publisher","first-page":"e2723","DOI":"10.1002\/pa.2723","volume":"21","author":"RE Hinson","year":"2021","unstructured":"Hinson RE, Hein W, Tettey LN, Nartey BA, Harant A, Struck NS, et al. Critical prerequisites for Covid-19 vaccine acceleration: a developing economy perspective. J Public Affairs. 2021;21(4):e2723\u2013na.","journal-title":"J Public Affairs"},{"key":"1096_CR54","unstructured":"Steingr\u00fcber S, Gadanya M. Weak links: how corruption affects the quality and integrity of medical products and impacts on the Covid-19 response. U4. 2021 [cited 2024 Apr 8];15."},{"key":"1096_CR55","unstructured":"US Government Accountability Office. COVID-19. Critical Vaccine Distribution, Supply Chain, Program Integrity, and Other Challenges Require Focused Federal Attention. Report to Congressional Committees. 2021[cited 2024 Apr 8]. Available from: https:\/\/files.gao.gov\/reports\/GAO-21-265\/index.html"},{"issue":"4","key":"1096_CR56","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/hpm.3464","volume":"37","author":"S Sachdev","year":"2022","unstructured":"Sachdev S, Viriyathorn S, Chotchoungchatchai S, Patcharanarumol W, Tangcharoensathien V. Thailand\u2019s COVID-19: how public financial management facilitated effective and accountable health sector responses. Int J Health Plann Manag. 2022;37(4):1894\u2013906.","journal-title":"Int J Health Plann Manag"},{"key":"1096_CR57","unstructured":"UNODC. Good Practices Compendium on Combating Corruption in the Response to COVID-19 [Internet]. G20 Saudi Arabia 2020 Riyadh Summit. 2020 [cited 2022 Jan 19]. Available from: https:\/\/www.unodc.org\/pdf\/corruption\/G20_Compendium_COVID-19_FINAL.pdf"},{"key":"1096_CR58","doi-asserted-by":"publisher","unstructured":"Parmaksiz K, Pisani E, Bal R, Kok MO. A systematic review of pooled procurement of medicines and vaccines: identifying elements of success. Global Health. 2022 Jun 11 [cited 2024 Apr 8];18(1):59. Available from: https:\/\/doi.org\/10.1186\/s12992-022-00847-z","DOI":"10.1186\/s12992-022-00847-z"},{"issue":"10","key":"1096_CR59","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2471\/BLT.21.285761","volume":"99","author":"S Vogler","year":"2021","unstructured":"Vogler S, Haasis MA, van den Ham R, Humbert T, Garner S, Suleman F, et al. European collaborations on medicine and vaccine procurement. Bull World Health Organ. 2021;99(10):715\u201321.","journal-title":"Bull World Health Organ"},{"key":"1096_CR60","unstructured":"PAHO, POOLED PROCUREMENT IN PANDEMIC PREPAREDNESS. AND RESPONSE: leveraging the PAHO Revolving Funds to strengthen health equity and resilience [Internet]. PAHO. 2022 [cited 2024 Apr 8]. Available from: https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/56946\/PAHOHSSSFCOVID19220036_eng.pdf?sequence=1_isAllowed=y"},{"key":"1096_CR61","unstructured":"World Bank. World Bank and IFRC Support Independent Monitoring of COVID-19 Vaccine Campaign in Lebanon [Internet]. 2021 Feb 12 [cited 2021 Oct 27]. Available from: https:\/\/www.worldbank.org\/en\/news\/press-release\/2021\/02\/12\/world-bank-and-ifrc-support-independent-monitoring-of-covid-19-vaccine-campaign-in-lebanon"},{"key":"1096_CR62","doi-asserted-by":"crossref","unstructured":"Naga Nithin G, Egala BS, Pradhan AK. Global Level Smart Vaccination Tracking System using Blockchain and IoT. In: 2021 IEEE International Symposium on Smart Electronic Systems (iSES). IEEE; 2021. pp. 450\u20135.","DOI":"10.1109\/iSES52644.2021.00106"},{"key":"1096_CR63","doi-asserted-by":"publisher","first-page":"71372","DOI":"10.1109\/ACCESS.2021.3079197","volume":"9","author":"A Musamih","year":"2021","unstructured":"Musamih A, Jayaraman R, Salah K, Hasan HR, Yaqoob I, Al-Hammadi Y. Blockchain-based solution for distribution and delivery of COVID-19 vaccines. IEEE Access. 2021;9:71372\u201387.","journal-title":"IEEE Access"},{"key":"1096_CR64","doi-asserted-by":"crossref","unstructured":"Meghla TI, Rahman MM, Biswas AA, Hossain JT, Khatun T. Supply Chain Management with Demand Forecasting of Covid-19 Vaccine using Blockchain and Machine Learning. In:, Technologies N. (ICCCNT). IEEE; 2021. pp. 01\u20137.","DOI":"10.1109\/ICCCNT51525.2021.9580006"},{"issue":"11","key":"1096_CR65","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3390\/vaccines9111239","volume":"9","author":"H Chauhan","year":"2021","unstructured":"Chauhan H, Gupta D, Gupta S, Singh A, Aljahdali HM, Goyal N, et al. Blockchain enabled transparent and anti-counterfeiting supply of COVID-19 vaccine vials. Vaccines (Basel). 2021;9(11):1239.","journal-title":"Vaccines (Basel)"},{"key":"1096_CR66","doi-asserted-by":"crossref","unstructured":"Antal CD, Cioara T, Antal M, Anghel I. Blockchain platform for COVID-19 vaccine supply management. 2021.","DOI":"10.1109\/OJCS.2021.3067450"},{"key":"1096_CR67","unstructured":"Cuadrado DC, Sejer\u00f8e D, Hausenkamph PA, Cardona C, Turati M, Pardo NM. Safeguarding the Covid-19 vaccine distribution: evaluating the role of blockchain. U4 2022 [cited 2024 Apr 8];7."},{"key":"1096_CR68","unstructured":"Kohler J, Martinez M, Petkov M, Sale J. Corruption in the Pharmaceutical Sector: Diagnosing the Challenges [Internet]. Transparency International. 2016 [cited 2022 Dec 17]. Available from: https:\/\/www.transparency.org.uk\/sites\/default\/files\/pdf\/publications\/29-06-2016-Corruption_In_The_Pharmaceutical_Sector_Web-2.pdf"},{"issue":"11","key":"1096_CR69","doi-asserted-by":"publisher","first-page":"782","DOI":"10.2471\/BLT.17.206516","volume":"96","author":"A Paschke","year":"2018","unstructured":"Paschke A, Dimancesco D, Vian T, Kohler JC, Forte G. Increasing transparency and accountability in national pharmaceutical systems. Bull World Health Organ. 2018;96(11):782\u201391.","journal-title":"Bull World Health Organ"},{"issue":"2","key":"1096_CR70","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1162\/qjec.2009.124.2.735","volume":"124","author":"M Bj\u00f6rkman","year":"2009","unstructured":"Bj\u00f6rkman M, Svensson J. Power to the people: evidence from a Randomized Field experiment on community-based monitoring in Uganda. Q J Econ. 2009;124(2):735\u201369.","journal-title":"Q J Econ"},{"issue":"1","key":"1096_CR71","doi-asserted-by":"publisher","first-page":"2140494","DOI":"10.1080\/16549716.2022.2140494","volume":"15","author":"T Vian","year":"2022","unstructured":"Vian T, Agnew B, McInnes K. Whistleblowing as an anti-corruption strategy in health and pharmaceutical organizations in low- and middle-income countries: a scoping review. Global Health Action. 2022;15(1):2140494\u20132140494.","journal-title":"Global Health Action"},{"key":"1096_CR72","doi-asserted-by":"crossref","unstructured":"Gottschalk P, Smith C. Detection of White-Collar corruption in public procurement in Norway: the role of whistleblowers. Int J Procure Manage. 2016; 9(4).","DOI":"10.1504\/IJPM.2016.077703"},{"key":"1096_CR73","unstructured":"Transparency International. Whistleblowing [Internet]. n.d. b [cited 2021 Nov 28]. Available from: https:\/\/www.transparency.org\/en\/our-priorities\/whistleblowing"},{"issue":"sup1","key":"1096_CR74","doi-asserted-by":"publisher","first-page":"1694744","DOI":"10.1080\/16549716.2019.1694744","volume":"13","author":"T Vian","year":"2020","unstructured":"Vian T. Anti-corruption, transparency and accountability in health: concepts, frameworks, and approaches. Global Health Action. 2020;13(sup1):1694744\u20131694744.","journal-title":"Global Health Action"},{"key":"1096_CR75","unstructured":"The Global Fund to Fight AIDS. Tuberculosis and Malaria. Civil Society [Internet]. n.d. [cited 2021 Nov 28]. Available from: https:\/\/www.theglobalfund.org\/en\/civil-society\/"}],"container-title":["Globalization and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12992-025-01096-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12992-025-01096-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12992-025-01096-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:32:41Z","timestamp":1741347161000},"score":1,"resource":{"primary":{"URL":"https:\/\/globalizationandhealth.biomedcentral.com\/articles\/10.1186\/s12992-025-01096-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1096"],"URL":"https:\/\/doi.org\/10.1186\/s12992-025-01096-6","relation":{},"ISSN":["1744-8603"],"issn-type":[{"value":"1744-8603","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the University of Toronto\u2019s Research Ethics Board (Protocol Reference # 00042039); all methods were performed in accordance with relevant guidelines and regulations. Ethics Approval was obtained on February 4, 2022 in advance of participant recruitment, which began in May 2022. Before each interview, participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}